Abeona Therapeutics Inc.(ABEO)Earnings, Financials & Key RatiosAbeona Therapeutics Inc. (ABEO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the rapid decline in cash reserves from $163.5 million in 2025Q2 to $61.4 million in 2026Q1, combined with regulatory uncertainty, suggests a high probability of future liquidity constraints.
Abeona Therapeutics Inc. (ABEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Abeona Therapeutics Inc. (ABEO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.30vs $0.33+9.1% | $9Mvs $5M+90.7% |
| Q2 2026 | Mar 17, 2026 | $0.34vs $0.35+2.9% | $5Mvs $4M+22.0% |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.27+63.0% | —vs $6M |
| Q3 2025 | Aug 14, 2025 | $1.71vs $0.39+538.5% | $400,000vs $7M-93.9% |
Recent stock market news and headlines for Abeona Therapeutics Inc. (ABEO)
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Key metrics vs top competitors for Abeona Therapeutics Inc. (ABEO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.55 | $373.32M | 6.49 | — | 1223.08% | 70.05% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — |
Abeona Therapeutics Inc. (ABEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Abeona Therapeutics Inc. (ABEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Apr 7, 2026·SEC
Mar 20, 2026·SEC
Get notified when ABEO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Abeona Therapeutics Inc. (ABEO) stock FAQ — growth, dividends, profitability & financials explained
Abeona Therapeutics Inc. (ABEO) reported $14.5M in revenue for fiscal year 2025. This represents a 8607% increase from $0.2M in 1996.
Yes, Abeona Therapeutics Inc. (ABEO) is profitable, generating $66.1M in net income for fiscal year 2025 (1223.1% net margin).
Abeona Therapeutics Inc. (ABEO) has a return on equity (ROE) of 70.0%. This is excellent, indicating efficient use of shareholder capital.
Abeona Therapeutics Inc. (ABEO) had negative free cash flow of $85.2M in fiscal year 2025, likely due to heavy capital investments.
